Only a day's stock of Covid-19 vaccines left in Delhi: Official data

Delhi has less than a day's stock of coronavirus vaccines left as over 1.31 lakh doses were administered on Friday, according to data shared by the government.

covaxin, bharat biotech, coronavirus vaccine, covid-19, vaccination
Press Trust of India New Delhi
1 min read Last Updated : Jul 10 2021 | 11:14 PM IST

Delhi has less than a day's stock of coronavirus vaccines left as over 1.31 lakh doses were administered on Friday, according to data shared by the government.

According to CoWIN portal, 79,626 vaccine doses were administered on Saturday, taking the total number of doses administered in the national capital to 88,90,766, of which 20,76,571 were second doses.

On Friday, 1,31,143 were administered, of which 35,802 were second doses, according to the vaccination bulletin issued by the Delhi government. The total number of doses administered on Friday stood at 88,10,952, of which 20,49,318 were second doses.

On the morning of Saturday, Delhi had 2,50,000 doses of Covaxin and 63,000 doses of Covishield.

Covaxin is being used to administer second dose only, since its stocks are limited and have irregular delivery cycles, the bulletin said.

(Only the headline and picture of this report may have been reworked by the Business Standard staff; the rest of the content is auto-generated from a syndicated feed.)

*Subscribe to Business Standard digital and get complimentary access to The New York Times

Smart Quarterly

₹900

3 Months

₹300/Month

SAVE 25%

Smart Essential

₹2,700

1 Year

₹225/Month

SAVE 46%
*Complimentary New York Times access for the 2nd year will be given after 12 months

Super Saver

₹3,900

2 Years

₹162/Month

Subscribe

Renews automatically, cancel anytime

Here’s what’s included in our digital subscription plans

Exclusive premium stories online

  • Over 30 premium stories daily, handpicked by our editors

Complimentary Access to The New York Times

  • News, Games, Cooking, Audio, Wirecutter & The Athletic

Business Standard Epaper

  • Digital replica of our daily newspaper — with options to read, save, and share

Curated Newsletters

  • Insights on markets, finance, politics, tech, and more delivered to your inbox

Market Analysis & Investment Insights

  • In-depth market analysis & insights with access to The Smart Investor

Archives

  • Repository of articles and publications dating back to 1997

Ad-free Reading

  • Uninterrupted reading experience with no advertisements

Seamless Access Across All Devices

  • Access Business Standard across devices — mobile, tablet, or PC, via web or app

More From This Section

Topics :CoronavirusCoronavirus TestsCoronavirus Vaccine

First Published: Jul 10 2021 | 11:14 PM IST

Next Story